Latest News

Amitesh Roy_thumbnail

InterAACT open for recruitment at several sites

InterAACT is an international, multicentre trial aiming to establish which chemotherapy regimen is more effective for rare inoperable …

Click here to read more

Dr Jenny Shannon_thumbnail

ACTICCA-1 open to recruitment

Recently, ACTICCA-1 was opened for recruitment for people with gallbladder carcinoma at the Bankstown and Lidcombe Hospital in …

Click here to read more

running website_2

Run or walk for research

Are you in the Sydney area? Why not join our No Gutsy No Glory team and run or …

Click here to read more

AHEPA event_small

AHEPA’s incredible support

AHEPA is the largest Hellenic Association in the world with branches in the USA, Canada, Greece, Cyprus, England, …

Click here to read more

Dr Jenny Shannon_thumbnail

TACTIC trial results published

Results from the TACTIC clinical trial were recently published in the Cancer Chemotherapy and Pharmacology Journal. In this …

Click here to read more

Nick_thumbnail

INTEGRATE trial results published

The manuscript about results of the AGITG INTEGRATE trial, “Regorafenib for the Treatment of Advanced Gastric Cancer (INTEGRATE): a …

Click here to read more

Minolta DSC

Volunteers needed for neuropathic symptoms study

  Phil Mendoza-Jones is a cancer survivor who commenced chemotherapy treatment in late 2004, completing it in April …

Click here to read more

David Goldstein thumbnail

New Pancreatic Cancer Treatment guidelines

Conjoint Professor David Goldstein New surgery guidelines have been developed by a team of leading Australian pancreatic cancer …

Click here to read more

Timeline Images1

Excellence and Innovation in GI cancer research since 1991

For 25 years, the Australasian Gastro-Intestinal Trials Group, our parent body, has been conducting and promoting clinical and …

Click here to read more

venook_infogram_1_thumbnail

Update on GI cancers

From June 3 – 7 more than 30,000 cancer specialists — including doctors, researchers, and patient advocates — …

Click here to read more